ACAD
31.92
-0.39
-1.21%
AEMD
3.89
0.00
0.00%
APRI
2.38
-0.48
-16.7797%
ARNA
1.355
-0.015
-1.095%
ATEC
3.48
-0.03
-0.85%
CNAT
4.547
-0.283
-5.8654%
CRXM
0.18
+0.01
+4.32%
CYTX
1.65
0.00
0.00%
DXCM
83.13
-1.03
-1.22%
GNMK
12.005
-0.645
-5.099%
HALO
10.91
-0.36
-3.19%
ILMN
159.97
-1.26
-0.78%
INNV
0.19
-0.01
-5.00%
INO
6.605
-0.135
-1.9985%
ISCO
1
+0.08
+8.68%
ISIS
0
0.00
0.00%
LGND
101.03
-1
-0.98%
LPTN
2.93
0.00
0.00%
MBVX
3.17
+0.01
+0.32%
MEIP
1.54
+0.01
+0.65%
MNOV
5.98
-0.12
-1.97%
MRTX
5.5
0.00
0.00%
MSTX
0.131
-0.005
-3.6900%
NBIX
40.77
-1.27
-3.02%
NUVA
70.095
-0.125
-0.178%
ONCS
1.28
-0.02
-1.92%
ONVO
3.47
-0.08
-2.25%
OREX
3.2
-0.28
-8.05%
OTIC
15.45
-0.2
-1.28%
QDEL
19.55
-0.19
-0.96%
RCPT
0
0.00
0.00%
RGLS
2.375
-0.025
-1.042%
RMD
62.98
-0.31
-0.49%
SCIE
0.001
0.00
-7.1429%
SPHS
3.1
-0.13
-4.02%
SRNE
5.345
-0.155
-2.818%
TROV
2.35
+0.00
+0.0043%
VICL
2.25
-0.02
-0.88%
ZGNX
9.35
-0.35
-3.61%
ACAD
31.92
-0.39
-1.21%
AEMD
3.89
0.00
0.00%
APRI
2.38
-0.48
-16.7797%
ARNA
1.355
-0.015
-1.095%
ATEC
3.48
-0.03
-0.85%
CNAT
4.547
-0.283
-5.8654%
CRXM
0.18
+0.01
+4.32%
CYTX
1.65
0.00
0.00%
DXCM
83.13
-1.03
-1.22%
GNMK
12.005
-0.645
-5.099%
HALO
10.91
-0.36
-3.19%
ILMN
159.97
-1.26
-0.78%
INNV
0.19
-0.01
-5.00%
INO
6.605
-0.135
-1.9985%
ISCO
1
+0.08
+8.68%
ISIS
0
0.00
0.00%
LGND
101.03
-1
-0.98%
LPTN
2.93
0.00
0.00%
MBVX
3.17
+0.01
+0.32%
MEIP
1.54
+0.01
+0.65%
MNOV
5.98
-0.12
-1.97%
MRTX
5.5
0.00
0.00%
MSTX
0.131
-0.005
-3.6900%
NBIX
40.77
-1.27
-3.02%
NUVA
70.095
-0.125
-0.178%
ONCS
1.28
-0.02
-1.92%
ONVO
3.47
-0.08
-2.25%
OREX
3.2
-0.28
-8.05%
OTIC
15.45
-0.2
-1.28%
QDEL
19.55
-0.19
-0.96%
RCPT
0
0.00
0.00%
RGLS
2.375
-0.025
-1.042%
RMD
62.98
-0.31
-0.49%
SCIE
0.001
0.00
-7.1429%
SPHS
3.1
-0.13
-4.02%
SRNE
5.345
-0.155
-2.818%
TROV
2.35
+0.00
+0.0043%
VICL
2.25
-0.02
-0.88%
ZGNX
9.35
-0.35
-3.61%
Home » Events, SDBN Events

SDBN Networking Event Featuring Fate Therapeutics & Stemgent

Submitted by on July 1, 2009 – 11:41 am

The San Diego Biotechnology Network’s July 21st event will feature Fate Therapeutics and Stemgent, two companies engaged in exciting, interdisciplinary biotechnology research in San Diego that holds direct promise for making a difference in our quality of life. Ken Batchelor, Ph.D., CSO, Fate Therapeutics, and Stephen Chang, Ph.D., CSO, Stemgent will present a short talk which will be followed by networking:

CATALYST: The Industrialization of Advanced iPSC Technology for Drug Discovery & Development

For more information visit http://sdbn.org/july

Be Sociable, Share!